# Motif Bio PLC Appoint Robert Dickey IV as Chief Financial Officer

- Link: https://www.directorstalkinterviews.com/motif-bio-plc-appoint-robert-dickey-iv-chief-financial-officer/412721336
- Published: 2017-01-18T07:20:12+00:00
- Author: Giles Arbor

**Motif Bio plc** (LON:MTFB), the clinical stage biopharmaceutical company specialising
in developing novel antibiotics, announces that Robert Dickey IV has been appointed
as Chief Financial Officer.

Mr. Dickey is an accomplished financial professional with senior leadership experience
in private and public healthcare companies. Prior to joining Motif Bio, he was CFO
at Tyme Technologies Inc., a NASDAQ-listed clinical stage oncology company. Robert
previously held senior leadership positions at NeoStem, Inc. (now known as Caladrius
Biosciences Inc.), Hemispherx Biopharma Inc., Stemcyte Inc., Locus Pharmaceuticals
Inc. and Protarga Inc. Mr. Dickey began his career as an Investment Banker at Lehman
Brothers and Legg Mason Wood Walker Inc.

Pete Meyers is leaving Motif Bio and has agreed to transition the CFO responsibilities
to Mr. Dickey over the course of the next several weeks.

> **Graham Lumsden, Motif Bio plc CEO commented:** “I am delighted that Rob has 
> agreed to join Motif Bio at this important time as we await data read-out in the
> second quarter of 2017 from REVIVE-1, our Phase 3 clinical trial in patients with
> ABSSSI (Acute Bacterial Skin and Skin Structure Infections). Rob’s proven leadership
> and strategic skills will be a tremendous addition to the team. I am immensely
> grateful to Pete Meyers for his tireless dedication and hard work during 2016,
> culminating in a successful NASDAQ IPO and raise of $25 million. I wish him well
> in his future endeavours.”

Share on: